Health Research International publishes reports on opportunities presented by transcatheter and minimally invasive surgical valve technologies

Transcatheter heart valve technologies are positioned to become the next disruptive influence in cardiovascular medicine and drive a multi-billion dollar market. However, questions remain about the timing of adoption of these new technologies, the numbers and types of patients ultimately benefitting from them, the impact of reimbursement, and where transcatheter technologies pose the greatest threat to the current surgical caseload, especially in light of developments in minimally invasive heart valve surgery technologies.

For companies seeking to capture the substantial opportunity presented by transcatheter and minimally invasive surgical valve technologies, Health Research International’s two new reports, distributed exclusively by Life Science Intelligence are must-have business intelligence. They present the future of heart valve therapy via 200 exhibits and in-depth analyses encompassing:

• Detailed evidence-based epidemiological data driving market development;
• Detailed analyses of clinical trial designs and outcomes for both transcatheter and minimally invasive surgical valve technologies that will impact product adoption and indications;
• Econometrically modeled forecasts of valve procedures by position, type and approach through 2015;
• Econometrically modeled forecasts of product markets by type, including relevant pricing and supplier shares; and
• Detailed profiles of more than 80 new technologies, both primary and adjunctive, as well as the companies developing them.

Additional details on these reports can be found at:

U.S. Opportunities in Transcatheter Heart Valve Technologies - www.LSintelligence.com

U.S. Opportunities in Surgical Heart Valve Technologies -